187 related articles for article (PubMed ID: 35900040)
1. Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study.
Christensen SF; Svingel LS; Kjaersgaard A; Stenling A; Darvalics B; Paulsson B; Andersen CL; Christiansen CF; Stentoft J; Starklint J; Severinsen MT; Clausen MB; Hilsøe MH; Hasselbalch HC; Frederiksen H; Mikkelsen EM; Bak M
Eur J Haematol; 2022 Nov; 109(5):526-541. PubMed ID: 35900040
[TBL] [Abstract][Full Text] [Related]
2. Labor market affiliation of patients with myeloproliferative neoplasms: a population-based matched cohort study.
Svingel LS; Christensen SF; Kjærsgaard A; Stenling A; Paulsson B; Andersen CL; Christiansen CF; Stentoft J; Starklint J; Severinsen MT; Borg Clausen M; Hagemann Hilsøe M; Hasselbalch HC; Frederiksen H; Bak M; Mikkelsen EM
Acta Oncol; 2023 Oct; 62(10):1286-1294. PubMed ID: 37656802
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada.
Bankar A; Zhao H; Iqbal J; Coxford R; Cheung MC; Mozessohn L; Earle CC; Gupta V
Leuk Lymphoma; 2020 Aug; 61(8):1908-1919. PubMed ID: 32323602
[TBL] [Abstract][Full Text] [Related]
4. Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan.
Mehta J; Wang H; Fryzek JP; Iqbal SU; Mesa R
Leuk Lymphoma; 2014 Oct; 55(10):2368-74. PubMed ID: 24450579
[TBL] [Abstract][Full Text] [Related]
5. Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.
Bak M; Sørensen TL; Flachs EM; Zwisler AD; Juel K; Frederiksen H; Hasselbalch HC
JAMA Ophthalmol; 2017 Aug; 135(8):835-843. PubMed ID: 28655032
[TBL] [Abstract][Full Text] [Related]
6. Risk of Inflammatory Bowel Disease in Patients with Chronic Myeloproliferative Neoplasms: A Danish Nationwide Cohort Study.
Bak M; Jess T; Flachs EM; Zwisler AD; Juel K; Frederiksen H
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32967227
[TBL] [Abstract][Full Text] [Related]
7. Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study.
Pedersen KM; Bak M; Sørensen AL; Zwisler AD; Ellervik C; Larsen MK; Hasselbalch HC; Tolstrup JS
Cancer Med; 2018 Nov; 7(11):5796-5802. PubMed ID: 30318865
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.
Larsen MK; Skov V; Kjær L; Eickhardt-Dalbøge CS; Knudsen TA; Kristiansen MH; Sørensen AL; Wienecke T; Andersen M; Ottesen JT; Gudmand-Høyer J; Snyder JA; Andersen MP; Torp-Pedersen C; Poulsen HE; Stiehl T; Hasselbalch HC; Ellervik C
Blood Cancer J; 2024 Feb; 14(1):28. PubMed ID: 38331919
[TBL] [Abstract][Full Text] [Related]
9. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Gerds AT; Gotlib J; Ali H; Bose P; Dunbar A; Elshoury A; George TI; Gundabolu K; Hexner E; Hobbs GS; Jain T; Jamieson C; Kaesberg PR; Kuykendall AT; Madanat Y; McMahon B; Mohan SR; Nadiminti KV; Oh S; Pardanani A; Podoltsev N; Rein L; Salit R; Stein BL; Talpaz M; Vachhani P; Wadleigh M; Wall S; Ward DC; Bergman MA; Hochstetler C
J Natl Compr Canc Netw; 2022 Sep; 20(9):1033-1062. PubMed ID: 36075392
[TBL] [Abstract][Full Text] [Related]
10. Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study.
Hur JY; Choi N; Choi JH; Kim J; Won YW
Thromb Res; 2024 Apr; 236():209-219. PubMed ID: 38461615
[TBL] [Abstract][Full Text] [Related]
11. Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.
Kaifie A; Isfort S; Gattermann N; Hollburg W; Klausmann M; Wolf D; Maintz C; Hänel M; Goekkurt E; Göthert JR; Platzbecker U; Geer T; Parmentier S; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
Ann Hematol; 2016 Sep; 95(9):1399-410. PubMed ID: 27334946
[TBL] [Abstract][Full Text] [Related]
12. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
13. Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis.
Pettersson H; Knutsen H; Holmberg E; Andréasson B
Eur J Haematol; 2015 Feb; 94(2):152-6. PubMed ID: 25039361
[TBL] [Abstract][Full Text] [Related]
14. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
15. Healthcare resource utilization among patients with cold agglutinin disease in Denmark.
Vágó EK; Nicholson G; Horváth-Puhó E; Hooda N; Fryzek JP; Su J
Curr Med Res Opin; 2021 Oct; 37(10):1829-1835. PubMed ID: 34308723
[TBL] [Abstract][Full Text] [Related]
16. Healthcare resource utilization prior to suicide death or suicide attempt in patients with major depressive disorder-A Danish registry-based cohort study.
Jensen KJ; Osler M; Bødker N; Riise J; Petersen J
Suicide Life Threat Behav; 2023 Jun; 53(3):399-414. PubMed ID: 36825304
[TBL] [Abstract][Full Text] [Related]
17. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
[TBL] [Abstract][Full Text] [Related]
18. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
19. Highly increased risk of fracture in patients with myeloproliferative neoplasm.
Johansson P; Kristjansdottir HL; Johansson H; Jakir A; Mellström D; Lewerin C
Leuk Lymphoma; 2021 Jan; 62(1):211-217. PubMed ID: 32909485
[TBL] [Abstract][Full Text] [Related]
20. Cerebrovascular events as presenting manifestations of Myeloproliferative Neoplasm.
Ong E; Barraco F; Nighoghossian N; Praire A; Desestret V; Derex L; Vighetto A; Biotti D
Rev Neurol (Paris); 2016 Nov; 172(11):703-708. PubMed ID: 28241944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
